Bone Marrow Mesenchymal Stem Cells Transfer in Patients With ST-segment Elevation Myocardial Infarction

• Status: Completed
• Trial end date: 2011-07-15
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the effect and safety of intracoronary autologous bone morrow mesenchymal stem cells (BM-MSCs) transplantation in patients with ST-segment elevation myocardial infarction（ STEMI） .

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Affiliated Hospital of North Sichuan Medical College
• Collaborators: Beijing Tongren Hospital; Chinese PLA General Hospital; Peking Union Medical College Hospital

Criteria

Inclusion Criteria:

• Age> 18 years old;

• Diagnosed acute ST-elevation myocardial infarction (STEMI)

• STEMI onset <1 month

• Successful vascular remodeling, blood flow of infarct-related blood vessels recovered to TIMI level 3

• All patients included in the study signed an informed consent form and promised to complete all follow-up plans

Exclusion Criteria:

• Refractory persistent ventricular tachycardia

• High cardiac block and no pacemaker control

• Liver or renal dysfunction (ALT>80U/ L, Cr> 440mmol / L)

• Bleeding disorders, malignant tumors

• Autoimmune disease or any serious fatal disease

• Contraindications for coronary intervention

• Combined with other heart disease: congenital heart Disease (ventricular deficiency, atrial deficient, patent ductus arteriosus and other congenital alformations),primary valvular disease, active myocarditis, pulmonary heart disease,hyperthyroidism, mucous edema heart disease and so on

• Mental illness, no self-awareness, and no precise expression and cooperation